Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone508-683-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.82 billion
Profitability
Miscellaneous
Employees32,000
Next Earnings Date10/23/2019 (Estimated)
OptionableOptionable
Boston Scientific (NYSE:BSX) Frequently Asked Questions
What is Boston Scientific's stock symbol?
Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."
How were Boston Scientific's earnings last quarter?
Boston Scientific Co. (NYSE:BSX) announced its quarterly earnings data on Wednesday, July, 24th. The medical equipment provider reported $0.39 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.38 by $0.01. The medical equipment provider had revenue of $2.63 billion for the quarter, compared to the consensus estimate of $2.64 billion. Boston Scientific had a return on equity of 23.29% and a net margin of 13.85%. Boston Scientific's quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.41 EPS. View Boston Scientific's Earnings History.
When is Boston Scientific's next earnings date?
What guidance has Boston Scientific issued on next quarter's earnings?
Boston Scientific issued an update on its FY19 earnings guidance on Wednesday, July, 24th. The company provided EPS guidance of $1.54-$1.58 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.57. The company issued revenue guidance of $10.55-$10.61 billion, compared to the consensus revenue estimate of $10.67 billion.
What price target have analysts set for BSX?
22 brokerages have issued 1-year target prices for Boston Scientific's stock. Their predictions range from $36.20 to $50.00. On average, they expect Boston Scientific's stock price to reach $45.2952 in the next year. This suggests a possible upside of 4.6% from the stock's current price. View Analyst Price Targets for Boston Scientific.
What is the consensus analysts' recommendation for Boston Scientific?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 18 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Boston Scientific.
What are Wall Street analysts saying about Boston Scientific stock?
Here are some recent quotes from research analysts about Boston Scientific stock:
- 1. Needham & Company LLC analysts commented, "BSX announced it is acquiring the private company up front cash and commercial-based milestones. Vertiflex’s Superion system is a minimally invasive device to treat patients with lumbar spinal stenosis (LSS). BSX expects the deal to be immaterial to its adjusted EPS through 2020 and accretive thereafter. While we are a little surprised to see BSX enter the spinal surgery market, there probably are synergies with its existing pain business and we see this deal as a typical BSX transaction in which it acquires an asset allowing it to go deeper within a disease state/disorder (in this case chronic pain). We expect BSX’s string of acquisitions over the past ~18 months (including Vertiflex) to combine to provide a material benefit to its longer-term organic growth and we reiterate our Strong Buy rating." (5/13/2019)
- 2. BTIG Research analysts commented, "$42 Story BSX results fell short of Street expectations on a myriad of items. Heading into the print, investors anticipated the paclitaxel and mesh issues but less selling days, a temporary supply issue and a weaker Neuromod result pressured Q1 incrementally. As we anticipated in our preview, BSX guided FY19 revenue growth to the bottom half of the prior range (7-8% from 7- 9%). We revised our estimates accordingly for known pressure points and while there could be upside from high-growth segments (Structural Heart remains likely), our view is that NT significant outperformance by BSX is less likely than it was six months ago. On lower forecasts and a slightly lower multiple, we trim our PT from $45 to $42. Some investors have asked if the growth acceleration story is over. We do not think so but we do think there will be a NT slowdown before potential acceleration." (4/25/2019)
- 3. According to Zacks Investment Research, "Boston Scientific is suffering from significant cost escalation, which is weighing on its margins. Also, delay in LOTUS relaunch is hampering sales through 2018. Declining worldwide pacemaker sales is also hurting the CRM business. On a brighter note, the company is seeing growth across all business lines and geographies. Boston Scientific received a number of FDA approvals within the Cardiovascular group. This apart, it launched LithoVue within Urology and rolled out the GUIDE XT in Europe. We look forward to the three recent acquisitions- Claret Medical, VENITI and Augmenix. These are expected to strongly contribute to the company’s inorganic growth profile. Boston Scientific’s significant progress related to its LOTUS valve relaunch encourages us. Also, post the suspension of LOTUS valve in Europe, ACURATE TAVR continues to build momentum. Over the past three months, Boston Scientific outperformed its industry." (1/7/2019)
Has Boston Scientific been receiving favorable news coverage?
Media stories about BSX stock have been trending negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Boston Scientific earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Boston Scientific.
Who are some of Boston Scientific's key competitors?
Some companies that are related to Boston Scientific include 3M (MMM), Stryker (SYK), Becton Dickinson and (BDX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Penumbra (PEN) and Integra Lifesciences (IART).
What other stocks do shareholders of Boston Scientific own?
Who are Boston Scientific's key executives?
Boston Scientific's management team includes the folowing people:
- Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 54)
- Mr. Daniel J. Brennan, Exec. VP & CFO (Age 53)
- Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 55)
- Mr. David A. Pierce, Exec. VP & Pres of MedSurg (Age 55)
- Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 46)
Who are Boston Scientific's major shareholders?
Boston Scientific's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.94%), BlackRock Inc. (7.94%), Vanguard Group Inc. (7.67%), Primecap Management Co. CA (3.24%), Janus Henderson Group PLC (2.82%) and Bank of New York Mellon Corp (1.27%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun, Wendy Carruthers, Xin Warren Wang and Yoshiaki Fujimori. View Institutional Ownership Trends for Boston Scientific.
Which institutional investors are selling Boston Scientific stock?
BSX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., BlackRock Inc., Putnam Investments LLC, Renaissance Technologies LLC, Amundi Pioneer Asset Management Inc., First Trust Advisors LP, AQR Capital Management LLC and Canada Pension Plan Investment Board. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Jodi Euerle Eddy, John Bradley Sorenson, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Xin Warren Wang and Yoshiaki Fujimori. View Insider Buying and Selling for Boston Scientific.
Which institutional investors are buying Boston Scientific stock?
BSX stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Viking Global Investors LP, Marshall Wace LLP, Invesco Ltd., Vontobel Asset Management Inc., Eminence Capital LP, Price T Rowe Associates Inc. MD and Vanguard Group Inc.. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific.
How do I buy shares of Boston Scientific?
Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Boston Scientific's stock price today?
One share of BSX stock can currently be purchased for approximately $43.29.
How big of a company is Boston Scientific?
Boston Scientific has a market capitalization of $60.30 billion and generates $9.82 billion in revenue each year. The medical equipment provider earns $1.67 billion in net income (profit) each year or $1.47 on an earnings per share basis. Boston Scientific employs 32,000 workers across the globe.View Additional Information About Boston Scientific.
What is Boston Scientific's official website?
How can I contact Boston Scientific?
Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]
MarketBeat Community Rating for Boston Scientific (NYSE BSX)
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
